viernes, 2 de noviembre de 2018

Follow the debate over Alkermes' controversial new depression drug - STAT

Follow the debate over Alkermes' controversial new depression drug - STAT

Daily Recap

STAT Plus: Follow the debate over Alkermes’ controversial new depression drug

By ADAM FEUERSTEIN AND DAMIAN GARDE


APSTOCK
The FDA is convening a panel of experts to review a new drug to combat treatment-resistant depression. We're following the discussion live.

No hay comentarios: